{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:05:44Z","timestamp":1781247944564,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate the association of patients\u2019 sex with recurrence and disease progression in patients treated with intravesical bacillus Calmette\u2013Gu\u00e9rin (BCG) for T1G3\/HG urinary bladder cancer (UBC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>We analyzed the data of 2635 patients treated with adjuvant intravesical BCG for T1 UBC between 1984 and 2019. We accounted for missing data using multiple imputations and adjusted for covariate imbalance between males and females using inverse probability weighting (IPW). Crude and IPW-adjusted Cox regression analyses were used to estimate the hazard ratios (HR) with their 95% confidence intervals (CI) for the association of patients\u2019 sex with HG-recurrence and disease progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 2170 (82%) males and 465 (18%) females were available for analysis. Overall, 1090 (50%) males and 244 (52%) females experienced recurrence, and 391 (18%) males and 104 (22%) females experienced disease progression. On IPW-adjusted Cox regression analyses, female sex was associated with disease progression (HR 1.25, 95%CI 1.01\u20131.56, <jats:italic>p<\/jats:italic>\u2009=\u20090.04) but not with recurrence (HR 1.06, 95%CI 0.92\u20131.22, <jats:italic>p<\/jats:italic>\u2009=\u20090.41). A total of 1056 patients were treated with adequate BCG. In these patients, on IPW-adjusted Cox regression analyses, patients\u2019 sex was not associated with recurrence (HR 0.99, 95%CI 0.80\u20131.24, <jats:italic>p<\/jats:italic>\u2009=\u20090.96), HG-recurrence (HR 1.00, 95%CI 0.78\u20131.29, <jats:italic>p<\/jats:italic>\u2009=\u20090.99) or disease progression (HR 1.12, 95%CI 0.78\u20131.60, <jats:italic>p<\/jats:italic>\u2009=\u20090.55).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our analysis generates the hypothesis of a differential response to BCG between males and females if not adequately treated. Further studies should focus on sex-based differences in innate and adaptive immune system and their association with BCG response.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-021-03653-1","type":"journal-article","created":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T05:02:46Z","timestamp":1615611766000},"page":"3337-3344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Association of patients\u2019 sex with treatment outcomes after intravesical bacillus Calmette\u2013Gu\u00e9rin immunotherapy for T1G3\/HG bladder cancer"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1625-1077","authenticated-orcid":false,"given":"David","family":"D\u2019Andrea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne J.","family":"Grotenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene K.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Malats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Di Stasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W. G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaques","family":"Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Karnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Varkarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Baniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Spahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ardelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Serretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Dalbagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Larr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Uno","family":"Malmstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,13]]},"reference":[{"key":"3653_CR1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 196:1021\u20131029. https:\/\/doi.org\/10.1016\/j.juro.2016.06.049","journal-title":"J Urol"},{"key":"3653_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM et al (2019) European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 Update. Eur Urol 76:639\u2013657. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.016","journal-title":"Eur Urol"},{"key":"3653_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1200\/jco.2014.57.6967","volume":"33","author":"W Martin-Doyle","year":"2015","unstructured":"Martin-Doyle W, Leow JJ, Orsola A et al (2015) Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 33:643\u2013650. https:\/\/doi.org\/10.1200\/jco.2014.57.6967","journal-title":"J Clin Oncol"},{"key":"3653_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","volume":"67","author":"P Gontero","year":"2015","unstructured":"Gontero P, Sylvester R, Pisano F et al (2015) Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette\u2013Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients. Eur Urol 67:74\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2014.06.040","journal-title":"Eur Urol"},{"key":"3653_CR5","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette\u2013Guerin: the CUETO scoring model. J Urol 182:2195\u20132203. https:\/\/doi.org\/10.1016\/j.juro.2009.07.016","journal-title":"J Urol"},{"key":"3653_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L et al (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non\u2013muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette\u2013Gu\u00e9rin. Eur Urol 69:60\u201369. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.045","journal-title":"Eur Urol"},{"key":"3653_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","volume":"32","author":"CD Hurst","year":"2017","unstructured":"Hurst CD, Alder O, Platt FM et al (2017) Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell 32:701-715.e7. https:\/\/doi.org\/10.1016\/j.ccell.2017.08.005","journal-title":"Cancer Cell"},{"key":"3653_CR8","doi-asserted-by":"publisher","first-page":"239.e1","DOI":"10.1016\/j.urolonc.2018.01.018","volume":"36","author":"D D\u2019Andrea","year":"2018","unstructured":"D\u2019Andrea D, Abufaraj M, Susani M et al (2018) Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: a clinical decision-making tool. Urol Oncol Semin Orig Investig 36:239.e1-239.e7. https:\/\/doi.org\/10.1016\/j.urolonc.2018.01.018","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"3653_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.eururo.2018.11.052","volume":"75","author":"M Abufaraj","year":"2018","unstructured":"Abufaraj M, Foerster B, Schernhammer E et al (2018) Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes. Eur Urol 75:649\u2013658. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.052","journal-title":"Eur Urol"},{"key":"3653_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrurol.2017.125","volume":"14","author":"M Moschini","year":"2017","unstructured":"Moschini M, D\u2019Andrea D, Korn S et al (2017) Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 14:651\u2013668. https:\/\/doi.org\/10.1038\/nrurol.2017.125","journal-title":"Nat Rev Urol"},{"key":"3653_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bju.14417","volume":"123","author":"A Mari","year":"2019","unstructured":"Mari A, Kimura S, Foerster B et al (2019) A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int 123:11\u201321. https:\/\/doi.org\/10.1111\/bju.14417","journal-title":"BJU Int"},{"key":"3653_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00345-017-2116-3","volume":"36","author":"M Abufaraj","year":"2018","unstructured":"Abufaraj M, Shariat SF, Foerster B et al (2018) Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. World J Urol 36:231\u2013240. https:\/\/doi.org\/10.1007\/s00345-017-2116-3","journal-title":"World J Urol"},{"key":"3653_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrurol.2015.232","volume":"12","author":"I Lucca","year":"2015","unstructured":"Lucca I, Klatte T, Fajkovic H et al (2015) Gender differences in incidence and outcomes of urothelial and kidney cancer. Nat Rev Urol 12:585\u2013592. https:\/\/doi.org\/10.1038\/nrurol.2015.232","journal-title":"Nat Rev Urol"},{"key":"3653_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","volume":"69","author":"J Dobruch","year":"2016","unstructured":"Dobruch J, Daneshmand S, Fisch M et al (2016) Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 69:300\u2013310. https:\/\/doi.org\/10.1016\/j.eururo.2015.08.037","journal-title":"Eur Urol"},{"key":"3653_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","volume":"62","author":"J Palou","year":"2012","unstructured":"Palou J, Sylvester RJ, Faba OR et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette\u2013Gu\u00e9rin. Eur Urol 62:118\u2013125. https:\/\/doi.org\/10.1016\/j.eururo.2011.10.029","journal-title":"Eur Urol"},{"key":"3653_CR16","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00345-012-0996-9","volume":"31","author":"LA Kluth","year":"2013","unstructured":"Kluth LA, Fajkovic H, Xylinas E et al (2013) Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 31:1029\u20131036. https:\/\/doi.org\/10.1007\/s00345-012-0996-9","journal-title":"World J Urol"},{"key":"3653_CR17","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/jco.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, B\u00f6hle A et al (2016) Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol 34:1935\u20131944. https:\/\/doi.org\/10.1200\/jco.2015.64.4070","journal-title":"J Clin Oncol"},{"key":"3653_CR18","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.eururo.2009.06.032","volume":"56","author":"C Bolenz","year":"2009","unstructured":"Bolenz C, Lotan Y, Ashfaq R, Shariat SF (2009) Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol 56:1093\u20131095. https:\/\/doi.org\/10.1016\/j.eururo.2009.06.032","journal-title":"Eur Urol"},{"key":"3653_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.06.001","author":"MJ Krimphove","year":"2019","unstructured":"Krimphove MJ, Szymaniak J, Marchese M et al (2019) Sex-specific differences in the quality of treatment of muscle-invasive bladder cancer do not explain the overall survival discrepancy. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2019.06.001","journal-title":"Eur Urol Focus"},{"key":"3653_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/blc-160052","volume":"2","author":"G Godoy","year":"2016","unstructured":"Godoy G, Gakis G, Smith CL, Fahmy O (2016) Effects of androgen and estrogen receptor signaling pathways on bladder cancer initiation and progression. Bladder Cancer 2:127\u2013137. https:\/\/doi.org\/10.3233\/blc-160052","journal-title":"Bladder Cancer"},{"key":"3653_CR21","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.euo.2020.08.013","volume":"3","author":"M Koti","year":"2020","unstructured":"Koti M, Ingersoll MA, Gupta S et al (2020) Sex differences in bladder cancer immunobiology and outcomes: a collaborative review with implications for treatment. Eur Urol Oncol 3:622\u2013630. https:\/\/doi.org\/10.1016\/j.euo.2020.08.013","journal-title":"Eur Urol Oncol"},{"key":"3653_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.eururo.2009.05.047","volume":"57","author":"P Mariappan","year":"2010","unstructured":"Mariappan P, Zachou A, Grigor KM, Group for the EU-O (2010) Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57:843\u2013849. https:\/\/doi.org\/10.1016\/j.eururo.2009.05.047","journal-title":"Eur Urol"},{"key":"3653_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.08.010","author":"F Soria","year":"2019","unstructured":"Soria F, D\u2019Andrea D, Moschini M et al (2019) Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients? Urol Oncol Semin Orig Investig. https:\/\/doi.org\/10.1016\/j.urolonc.2019.08.010","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"3653_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2016.12.004","author":"MW Kramer","year":"2017","unstructured":"Kramer MW, Altieri V, Hurle R et al (2017) Current evidence of transurethral en-bloc resection of nonmuscle invasive bladder cancer. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2016.12.004","journal-title":"Eur Urol Focus"},{"key":"3653_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1464-410x.2009.09137.x","volume":"106","author":"SA Boorjian","year":"2009","unstructured":"Boorjian SA, Zhu F, Herr HW (2009) The effect of gender on response to bacillus Calmette\u2013Gu\u00e9rin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int 106:357\u2013361. https:\/\/doi.org\/10.1111\/j.1464-410x.2009.09137.x","journal-title":"BJU Int"},{"key":"3653_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","volume":"68","author":"L Mart\u00ednez-Pi\u00f1eiro","year":"2015","unstructured":"Mart\u00ednez-Pi\u00f1eiro L, Portillo JA, Fern\u00e1ndez JM et al (2015) Maintenance therapy with 3-monthly bacillus Calmette\u2013Gu\u00e9rin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO Study 98013. Eur Urol 68:256\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2015.02.040","journal-title":"Eur Urol"},{"key":"3653_CR27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2012","unstructured":"Oddens J, Brausi M, Sylvester R et al (2012) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette\u2013Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63:462\u2013472. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.039","journal-title":"Eur Urol"},{"key":"3653_CR28","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.juro.2016.10.061","volume":"197","author":"R Chou","year":"2017","unstructured":"Chou R, Selph S, Buckley DI et al (2017) Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: systematic review and meta-analysis. J Urol 197:548\u2013558. https:\/\/doi.org\/10.1016\/j.juro.2016.10.061","journal-title":"J Urol"},{"key":"3653_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","volume":"198","author":"BE Boehm","year":"2017","unstructured":"Boehm BE, Cornell JE, Wang H et al (2017) Efficacy of bacillus Calmette\u2013Gu\u2019erin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. J Urol 198:503\u2013510. https:\/\/doi.org\/10.1016\/j.juro.2017.01.086","journal-title":"J Urol"},{"key":"3653_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.10.021","author":"D D\u2019Andrea","year":"2019","unstructured":"D\u2019Andrea D, Soria F, Abufaraj M et al (2019) Comparative effectiveness of intravesical BCG-Tice and BCG-Moreau in patients with non-muscle invasive bladder cancer. Clin Genitourin Cancer. https:\/\/doi.org\/10.1016\/j.clgc.2019.10.021","journal-title":"Clin Genitourin Cancer"},{"key":"3653_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.21037\/tau.2018.08.19","volume":"8","author":"D Dndrea","year":"2018","unstructured":"Dndrea D, Gontero P, Shariat SF, Soria F (2018) Intravesical bacillus Calmette\u2013Gu\u00e9rin for bladder cancer: are all the strains equal? Transl Androl Urol 8:85\u201393. https:\/\/doi.org\/10.21037\/tau.2018.08.19","journal-title":"Transl Androl Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03653-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-021-03653-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03653-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T01:42:12Z","timestamp":1634089332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-021-03653-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,13]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["3653"],"URL":"https:\/\/doi.org\/10.1007\/s00345-021-03653-1","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,13]]},"assertion":[{"value":"14 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This retrospective study was conducted on already available data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not necessary as this is a retrospective analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}